SYRE
Spyre Therapeutics, Inc. Common Stock
stockNASDAQ
aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer's metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 93.19 | 2026-10-02 | -7.96% | -1.427 |
| 1M | 88.71 | 2026-09-10 | -3.31% | 0.990 |
| 3M | 97.74 | 2026-07-10 | -12.24% | 1.225 |
| 6M | 51.29 | 2026-04-10 | +67.23% | 1.845 |
| 1Y | 19.14 | 2025-10-10 | +348.14% | 1.734 |
| 2Y | 27.22 | 2024-10-10 | +215.12% | — |
Spyre Therapeutics, Inc. Common Stock (NASDAQ:SYRE) stock price today is $85.78, and today's volume is 1,116,438. SYRE is up 7.353% today. The 30 day average volume is 1.46M. SYRE market cap is $7.92B with 92.29M shares outstanding.